The potential role of these angiogenic circulating and inflammatory biomarkers in SSc screening is supported by numerous clinical studies, which have shown high levels of soluble vascular endothelial growth factor (VEGF) receptor 1 (sVEGFR1) [78,79] in patients predisposed to the development of PAH [80]. The gene discussed is VEGFA; the disease is pulmonary arterial hypertension.